Sedana Medical's Sedaconda study post-hoc analysis published in the Journal of Critical Care
Sedana Medical AB (publ) announces the publication of a post-hoc analysis of the company's pivotal Sedaconda study (SED001) in the Journal of Critical Care. The post-hoc analysis that focused on long-term outcomes demonstrated 3.5 more ICU-free days and less additional sedative use for mechanically ventilated intensive care unit (ICU) patients treated with isoflurane as the main sedative in comparison to patients receiving propofol as the main sedative.The publication, entitled “ICU- and ventilator-free days with isoflurane or propofol as a primary sedative - A post-hoc analysis of a